Short Interest in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Rises By 148.7%

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the recipient of a large growth in short interest during the month of June. As of June 30th, there was short interest totalling 29,100 shares, a growth of 148.7% from the June 15th total of 11,700 shares. Based on an average daily trading volume, of 30,100 shares, the short-interest ratio is presently 1.0 days. Currently, 0.2% of the company’s shares are sold short.

Cyclo Therapeutics Stock Performance

CYTH opened at $1.26 on Friday. The company has a fifty day moving average price of $1.30 and a two-hundred day moving average price of $1.48. The firm has a market capitalization of $36.06 million, a PE ratio of -1.26 and a beta of -0.33. Cyclo Therapeutics has a 52 week low of $0.89 and a 52 week high of $2.12.

Cyclo Therapeutics (NASDAQ:CYTH) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.05. The business had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.44 million. Cyclo Therapeutics had a negative return on equity of 2,741.89% and a negative net margin of 1,720.76%. Equities analysts forecast that Cyclo Therapeutics will post -0.62 EPS for the current year.

Institutional Trading of Cyclo Therapeutics

An institutional investor recently bought a new position in Cyclo Therapeutics stock. Founders Fund VI Management LLC bought a new stake in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 110,023 shares of the company’s stock, valued at approximately $175,000. Cyclo Therapeutics makes up about 1.4% of Founders Fund VI Management LLC’s investment portfolio, making the stock its 2nd largest position. Founders Fund VI Management LLC owned approximately 0.48% of Cyclo Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 68.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on CYTH. Ascendiant Capital Markets initiated coverage on Cyclo Therapeutics in a research report on Monday, April 22nd. They set a “buy” rating and a $2.60 target price for the company. HC Wainwright reissued a “buy” rating and set a $3.00 price objective on shares of Cyclo Therapeutics in a report on Friday, May 31st.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.